Moderna CEO Stéphane Bancel received an annual compensation package worth $19.87 million last year, the largest he’s ever ...

CompanyOverview|NASDAQ:MRNA] The CEO of Moderna Inc. (NASDAQ: MRNA) just purchased $5 million of stock in the open market.

CEO Stephane Bancel has bought stock for the first time on the open market since he was named the top executive in October ...

Five years after the start of the pandemic, the fight over who owns the underlying technologies that made the Covid-19 ...

Despite high R&D spending and cash burn, Moderna aims for breakeven by 2028, driven by new vaccine opportunities. Explore ...

Shares of the American pharmaceutical company Moderna (MRNA) climbed over 8% in pre-market trading following strategic ...

Moderna CEO Stéphane Bancel kept it short and sweet when asked about any communications with the new presidential administration during the company’s 2024 full-year earnings call on Friday ...

Moderna (MRNA) stock in focus as the company aims a 2027 marketing nod for Merck (MRK) partnered skin cancer vaccine. Read ...

But in 2025, Moderna aims to reduce cash cost expenses by $1 billion, CEO Stéphane Bancel said at the J.P. Morgan Healthcare Conference in January. The company will report its 2024 full-year ...

Details of Insider Purchases at Moderna According to the recent filing with the Securities and Exchange Commission (SEC), the company’s CEO, Stephane Bancel, and board director, Paul Sagan ...